ALNY:NGS-Alnylam Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 269.21

Change

-11.75 (-4.18)%

Market Cap

USD 3.92B

Volume

1.07M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 69.68B
ARGX argenx NV ADR

N/A

USD 37.97B
ONC BeiGene, Ltd.

N/A

USD 28.70B
RPRX Royalty Pharma Plc

N/A

USD 19.31B
SMMT Summit Therapeutics PLC

N/A

USD 14.57B
UTHR United Therapeutics Corporatio..

N/A

USD 14.37B
INCY Incyte Corporation

N/A

USD 14.22B
MRNA Moderna Inc

N/A

USD 13.74B
INSM Insmed Inc

N/A

USD 13.70B

ETFs Containing ALNY

MSGR 6.64 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 4.93 % 0.00 %

N/A

USD 5.16M
GNOG:LSE Global X Genomics & Biote.. 4.75 % 0.00 %

N/A

USD 9.10M
BBH VanEck Biotech ETF 3.92 % 0.35 %

N/A

USD 0.40B
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

N/A

N/A
GN0M:XETRA Global X Genomics & Biote.. 3.89 % 0.00 %

N/A

USD 7.05M
IBB iShares Biotechnology ETF 3.26 % 0.47 %

N/A

USD 6.00B
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 2.36 % 0.95 %

N/A

USD 0.06B
EQJS:LSE Invesco NASDAQ Next Gener.. 2.35 % 0.00 %

N/A

USD 0.05B
CURE:AU ETFS S&P Biotech ETF 2.32 % 0.00 %

N/A

USD 0.04B
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

N/A

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

N/A

N/A
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.07 % 0.00 %

N/A

USD 0.05B
WBIO:LSE WisdomTree BioRevolution .. 2.02 % 0.00 %

N/A

USD 4.04M
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

N/A

N/A
DOCG:LSE L&G Healthcare Breakthrou.. 1.97 % 0.00 %

N/A

USD 0.06B
DOCT:LSE L&G Healthcare Breakthrou.. 1.97 % 0.00 %

N/A

USD 0.06B
TMFX Motley Fool Next Index ET.. 1.66 % 0.00 %

N/A

USD 0.03B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

N/A

N/A
THNZ:XETRA 0.87 % 0.00 %

N/A

N/A
ETHO Amplify ETF Trust 0.00 % 0.45 %

N/A

USD 0.18B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

N/A

N/A
LABS 0.00 % 0.45 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.66B
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

N/A

USD 0.06B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.05B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

N/A

USD 0.60B
QQQN 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.41% 85% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.41% 85% B 87% B+
Trailing 12 Months  
Capital Gain 74.37% 92% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.37% 92% A 93% A
Trailing 5 Years  
Capital Gain 158.36% 88% B+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 158.36% 88% B+ 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 16.40% 64% D 70% C-
Dividend Return 16.40% 64% D 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.17% 87% B+ 64% D
Risk Adjusted Return 56.22% 96% N/A 81% B-
Market Capitalization 3.92B 99% N/A 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 476.14 1% 0%
Price / Cash Flow Ratio -3,843.06 100% 100%
Price/Free Cash Flow Ratio 204.85 1% 2%
Management Effectiveness  
Return on Equity -1,500.66% 4% 2%
Return on Invested Capital -29.19% 70% 30%
Return on Assets -2.74% 93% 46%
Debt to Equity Ratio 1,527.28% 2% 1%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.